ES2284935T3 - Composicion farmaceutica que comprende quitooligomeros. - Google Patents
Composicion farmaceutica que comprende quitooligomeros. Download PDFInfo
- Publication number
- ES2284935T3 ES2284935T3 ES02777769T ES02777769T ES2284935T3 ES 2284935 T3 ES2284935 T3 ES 2284935T3 ES 02777769 T ES02777769 T ES 02777769T ES 02777769 T ES02777769 T ES 02777769T ES 2284935 T3 ES2284935 T3 ES 2284935T3
- Authority
- ES
- Spain
- Prior art keywords
- chitooligomers
- treatment
- chitin
- oligomers
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 40
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 38
- 229920002101 Chitin Polymers 0.000 claims abstract description 34
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 32
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 31
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960002442 glucosamine Drugs 0.000 claims abstract description 25
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 24
- 230000006196 deacetylation Effects 0.000 claims abstract description 19
- 238000003381 deacetylation reaction Methods 0.000 claims abstract description 19
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 15
- 208000012659 Joint disease Diseases 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 24
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 31
- 229920001661 Chitosan Polymers 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- 108010022172 Chitinases Proteins 0.000 description 12
- 102000012286 Chitinases Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229920002674 hyaluronan Polymers 0.000 description 12
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 12
- 229940099552 hyaluronan Drugs 0.000 description 12
- 239000000178 monomer Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 6
- 101710128038 Hyaluronan synthase Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- XHMJOUIAFHJHBW-VFUOTHLCSA-N glucosamine 6-phosphate Chemical compound N[C@H]1[C@H](O)O[C@H](COP(O)(O)=O)[C@H](O)[C@@H]1O XHMJOUIAFHJHBW-VFUOTHLCSA-N 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 101710203678 Chitinase-like protein Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 150000008273 hexosamines Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 1
- 102100037839 Acidic mammalian chitinase Human genes 0.000 description 1
- 101710178876 Acidic mammalian chitinase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000003967 CLP Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000005469 Chitin Synthase Human genes 0.000 description 1
- 108700040089 Chitin synthases Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 101100377506 Drosophila melanogaster 14-3-3zeta gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 101710157310 Tegument protein UL47 homolog Proteins 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- -1 acid hydrochloric Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WMWKTCPGFOEPBD-YGIWDPDDSA-N azane;(2s,3s,4s,5r,6r)-6-[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound N.C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WMWKTCPGFOEPBD-YGIWDPDDSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108010040093 cellulose synthase Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 101150038575 clpS gene Proteins 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000007861 trimeric product Substances 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS6085A IS6085A (is) | 2001-09-26 | 2001-09-26 | Lyfjablanda með kítósan óligómerum |
| IS608501 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2284935T3 true ES2284935T3 (es) | 2007-11-16 |
Family
ID=36700489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02777769T Expired - Lifetime ES2284935T3 (es) | 2001-09-26 | 2002-09-26 | Composicion farmaceutica que comprende quitooligomeros. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7985741B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1435976B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4613008B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040062548A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE359797T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2507926C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60219653T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1435976T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2284935T3 (cg-RX-API-DMAC7.html) |
| IS (2) | IS6085A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1435976E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1435976T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003026677A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2507870A1 (en) * | 2001-12-13 | 2003-07-03 | Ism Biopolymer Inc. | Method of modulating release of saccharides and uses thereof |
| GB0321996D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Nutrition Ag | Organic compounds |
| CA2540586A1 (en) * | 2003-10-01 | 2005-04-21 | Optimer Pharmaceuticals, Inc. | Treatment of a condition in a mammal with administration of aminosugar and uses thereof |
| JP2007525486A (ja) * | 2003-11-24 | 2007-09-06 | オプティマー・ファーマスーティカルズ・インコーポレイテッド | 化合物の投与による哺乳動物の症状の処置及び化合物の使用方法 |
| WO2005112948A1 (ja) * | 2004-05-21 | 2005-12-01 | Tottori University | 創傷の治療又は処置のための薬剤 |
| BRPI0612034A2 (pt) * | 2005-06-14 | 2012-08-28 | Genis Ehf | método para recuperar polìmero de quitina parcialmente desacetilado totalmente solúvel e elevadamente puro, composição de polìmero de quitina parcialmente desacetilado, e, composição farmacêutica |
| US7485718B2 (en) | 2005-06-16 | 2009-02-03 | E. I. Du Pont De Nemours And Company | Chemical synthesis of low molecular weight polyglucosamines and polygalactosamines |
| WO2007001283A2 (en) * | 2005-06-16 | 2007-01-04 | E.I. Dupont De Nemours And Company | Chemical synthesis of low molecular weight polyglucosamines and polygalactosamines |
| KR100831335B1 (ko) * | 2006-06-22 | 2008-05-22 | 부경대학교 산학협력단 | 인간 피부 섬유아세포에서 메트릭스메탈로프로테이나제-2의 발현 및 활성을 억제시키는키토올리고사카라이드 화합물 및 이를 함유한 메트릭스메탈로프로테이나제-2 억제제 |
| CA2731201C (en) * | 2008-07-18 | 2018-10-16 | Genis Ehf. | Composition for treating autoimmune disorders |
| KR20100060634A (ko) * | 2008-11-28 | 2010-06-07 | (주)아모레퍼시픽 | 미토콘드리아 활성화를 위한 조성물 |
| KR101729137B1 (ko) * | 2009-07-28 | 2017-04-26 | (주)아모레퍼시픽 | 키토올리고당을 함유하는 피로회복용 조성물 |
| WO2012167226A2 (en) | 2011-06-03 | 2012-12-06 | Maguire Abbey, Llc | Method, composition, and articles for improving joint lubrication |
| NZ737873A (en) | 2011-09-08 | 2019-05-31 | Novozymes Bioag As | Seed treatment methods and compositions |
| CN104093680B (zh) | 2011-09-14 | 2016-08-24 | 诺维信生物农业公司 | 组合使用脂壳寡糖和/或壳寡糖与解磷微生物促植物生长 |
| WO2013044208A2 (en) | 2011-09-23 | 2013-03-28 | Novozymes Biologicals Holdings A/S | Chitooligosaccharides and methods for use in enhancing plant growth |
| CA2849901A1 (en) * | 2011-09-23 | 2013-03-28 | Novozymes Bioag A/S | Chitooligosaccharides and methods for use in enhancing corn growth |
| CN104470550A (zh) | 2012-04-23 | 2015-03-25 | 杰尼斯公共有限公司 | 作为骨移植替代物的含有部分脱乙酰壳多糖的自硬化生物活性接合剂组合物 |
| JP6285497B2 (ja) * | 2016-06-07 | 2018-02-28 | 株式会社エバーライフ | 鶏冠抽出物含有経口組成物及び鶏冠抽出物の香味に由来する摂取困難性の改善方法 |
| KR101673368B1 (ko) | 2016-07-14 | 2016-11-08 | 김기혁 | 공정가스 반응물의 콜드트랩 장치 |
| WO2023205718A2 (en) * | 2022-04-21 | 2023-10-26 | Hassan Ameer E | Methods of treating inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5919122B2 (ja) * | 1976-10-12 | 1984-05-02 | 味の素株式会社 | 水溶性部分脱アセチル化キチン及びその製造法 |
| US4532134A (en) * | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| JP2527317B2 (ja) * | 1986-12-19 | 1996-08-21 | ライオン株式会社 | 骨疾患治療剤 |
| US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| US6117851A (en) * | 1996-12-13 | 2000-09-12 | Lescarden Inc. | Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine |
| JP3062592B2 (ja) * | 1997-05-30 | 2000-07-10 | 農林水産省食品総合研究所長 | ２−アセチルアミノ−４−Ｏ−（２−アミノ−２−デオキシ−β−Ｄ −グルコピラノシル）−２−デオキシ−Ｄ −グルコースおよびその塩の製造法 |
| US6492350B2 (en) * | 2000-01-27 | 2002-12-10 | Jdc (Hawaii) Inc. | Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain |
| EP1127574A1 (en) * | 2000-02-22 | 2001-08-29 | Food Industry Research and Development Institute | Use of chitinous materials for inhibiting cellular nitric oxide production |
| CA2313836C (en) * | 2000-03-15 | 2009-06-09 | Cargill, Incorporated | Chitosan and method of preparing chitosan |
| US20020119949A1 (en) | 2001-02-26 | 2002-08-29 | Asa Hellman | Prophylactic teat treatment |
| BRPI0612034A2 (pt) * | 2005-06-14 | 2012-08-28 | Genis Ehf | método para recuperar polìmero de quitina parcialmente desacetilado totalmente solúvel e elevadamente puro, composição de polìmero de quitina parcialmente desacetilado, e, composição farmacêutica |
-
2001
- 2001-09-26 IS IS6085A patent/IS6085A/is unknown
-
2002
- 2002-09-26 SI SI200230558T patent/SI1435976T1/sl unknown
- 2002-09-26 AT AT02777769T patent/ATE359797T1/de active
- 2002-09-26 CA CA2507926A patent/CA2507926C/en not_active Expired - Lifetime
- 2002-09-26 DE DE60219653T patent/DE60219653T2/de not_active Expired - Lifetime
- 2002-09-26 ES ES02777769T patent/ES2284935T3/es not_active Expired - Lifetime
- 2002-09-26 US US10/490,637 patent/US7985741B2/en active Active
- 2002-09-26 EP EP02777769A patent/EP1435976B1/en not_active Expired - Lifetime
- 2002-09-26 JP JP2003530312A patent/JP4613008B2/ja not_active Expired - Lifetime
- 2002-09-26 WO PCT/IS2002/000016 patent/WO2003026677A1/en not_active Ceased
- 2002-09-26 PT PT02777769T patent/PT1435976E/pt unknown
- 2002-09-26 KR KR10-2004-7004323A patent/KR20040062548A/ko not_active Ceased
- 2002-09-26 DK DK02777769T patent/DK1435976T3/da active
-
2004
- 2004-03-22 IS IS7193A patent/IS2783B/is unknown
-
2011
- 2011-06-20 US US13/164,397 patent/US8415326B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8415326B2 (en) | 2013-04-09 |
| IS2783B (is) | 2012-05-15 |
| US20050004073A1 (en) | 2005-01-06 |
| US20110257381A1 (en) | 2011-10-20 |
| KR20040062548A (ko) | 2004-07-07 |
| IS7193A (is) | 2004-03-22 |
| IS6085A (is) | 2003-03-27 |
| ATE359797T1 (de) | 2007-05-15 |
| CA2507926A1 (en) | 2003-04-03 |
| EP1435976B1 (en) | 2007-04-18 |
| CA2507926C (en) | 2011-12-20 |
| PT1435976E (pt) | 2007-06-28 |
| JP2005507891A (ja) | 2005-03-24 |
| DK1435976T3 (da) | 2007-08-27 |
| JP4613008B2 (ja) | 2011-01-12 |
| SI1435976T1 (sl) | 2007-08-31 |
| DE60219653D1 (de) | 2007-05-31 |
| DE60219653T2 (de) | 2008-01-03 |
| WO2003026677A1 (en) | 2003-04-03 |
| EP1435976A1 (en) | 2004-07-14 |
| US7985741B2 (en) | 2011-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2284935T3 (es) | Composicion farmaceutica que comprende quitooligomeros. | |
| US20220177655A1 (en) | Method for deacetylation of biopolymers | |
| TR201909909T4 (tr) | Oligosakkarit- protein konjugeleri. | |
| JPWO2002004471A1 (ja) | ヒアルロン酸オリゴ糖画分およびそれを含む医薬 | |
| Hirano et al. | Cosmetic and pharmaceutical uses of chitin and chitosan | |
| RU2303984C2 (ru) | Сверхразветвленный амилопектин для применения в способах хирургического или терапевтического лечения млекопитающих, или в диагностических методах, особенно для применения в качестве объемного плазмозаменителя | |
| Ibram | Studies on chitosan, chitin and chitooligosaccharides and their biomedical properties | |
| Endo et al. | Synthesis of neoproteoglycans using the transglycosylation reaction as a reverse reaction of endo-glycosidases | |
| JP3955652B2 (ja) | 合成アミノ糖類誘導体及びその製造方法 | |
| JPH02107601A (ja) | 新規なキトサン化合物、その製造方法および保湿剤としての用途 | |
| Bahrke | Mass spectrometric analysis of chitooligosaccharides and their interaction with proteins | |
| JP4462826B2 (ja) | 骨疾患治療剤 | |
| Moussa | Synthesis and characterization of chitosan oligomers for biomedical applications | |
| JPH06277085A (ja) | 低分子量分岐β−１，３−グルカン及び分岐ラミナリオリゴ糖の製造方法 | |
| JP5646164B2 (ja) | 分岐キトサン誘導体 | |
| Kren | Enzymatic Synthesis of Carbohydrate Ligands for Natural Killer Cells: The Way from Ligand Optimisation Towards Anticancer Glycodrugs | |
| US20120289477A1 (en) | Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof | |
| Sturabotti | Functionalization of hyaluronic acid with a chondroprotective molecule and preparation of sulfonated HA-based materials | |
| JP2005139409A (ja) | デルマタン硫酸の製法 | |
| JPH01112995A (ja) | 高級ｎ−アセチルキトオリゴ糖の製造法 | |
| CN104788585A (zh) | 一种氨基葡萄糖合成甲壳素及其衍生物的方法 | |
| CN118852492A (zh) | 一种岩藻糖化硫酸乙酰肝素及其制备方法与应用 | |
| Hirano et al. | ingredients because of their biodegradable, biocompatible, viscosity and moisture-holding properties. Some commercial | |
| Spickenreither | Inhibitors of bacterial and mammalian hyaluronidases: design, synthesis and structure-activity relationships with focus on human enzymes | |
| KREN | Institute of Microbiology, Laboratory of Biotransformation Academy of Sciences of the Czech Republic |